Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Ex Input:
The Rebellion was the career highlight for both leaders; Cumberland resigned from the Army in 1757 and died of a stroke in 1765. Charles was initially treated as a hero on his return to Paris but the Stuarts were once again barred from France by the 1748 Treaty of Aix-la-Chapelle. Henry Stuart's entry into the Catholic Church in June 1747 was seen as tacit acceptance the Jacobites were finished and Charles never forgave him. He continued attempts to reignite the cause, including a secret visit to London in 1750 but habitual heavy drinking made him argumentative and hard to work with. In 1759, he met French Chief Minister de Choiseul to discuss another invasion attempt but Choiseul dismissed him as incapable through drink. When his father James died in 1766, Pope Clement XIII refused to recognise him as Charles III, despite the strong objections of his brother Henry. Charles never visited Britain again and died in Rome in January 1788, a disappointed and embittered man.

Ex Output:
Which happened first, Charles secret visit to London or his meeting with French Chief Minister de Choiseul?


Ex Input:
Robert Edward Chambliss (January 14, 1904 -- October 29, 1985), also known as Dynamite Bob, was convicted in 1977 of murder for his role as conspirator in the 16th Street Baptist Church bombing in 1963.

Ex Output:
Which crime led to the conviction of Robert Edward Chambliss?


Ex Input:
Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Imatinib induces complete haematological and cytogenetic response in high percentage of patients. The aim of this study was to identify potential prognostic factors before beginning treatment with imatinib associated with complete cytogenetic response. We analyzed 20 patients with newly diagnosed Philadelphia positive chronic myelogenous leukemia treated at our institution from June 2006 until May 2009. These patients were treated with imatinib mesylate in oral dose of 400 to 800 mg daily. Complete blood counts were performed every month, while serum chemistry evaluations and bone marrow evaluations including morphology and cytogenetics were performed every 6 months. Of the 20 patients analyzed in this study, 19 (95%) achieved complete haematologic response within three months. In all patients cytogenetic analyses were done and all have achieved absolute cytogenetic response. The best cytogenetic response rate at any time during study treatment among 20 patients was: complete cytogenetic response in 15, partial cytogenetic response in three and minor cytogenetic response in two patients. Among 11 observed base-line patients' characteristics five were independent predictors of a high rate of complete cytogenetic response; the absence of blasts and basophils in peripheral blood, the presence of less than 5 percent of bone marrow blasts, white blood cell count less than 10 x 10(9)/L and the absence of splenomegaly (p < 0.01). Our results showed that some pre-treatment characteristics of patients might be the cause of differences in treatment outcome. On the basis of this analysis, we identified several pre-treatment patients' characteristics to be independent prognostic factors for achievement of complete cytogenetic response.

Ex Output:

What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?